{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+3%29&page=25",
    "query": {
      "intervention": "Placebo (Cohort 3)",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 1069,
    "total_pages": 107,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+3%29&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+3%29&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T11:13:45.004Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03938246",
      "title": "Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)"
      ],
      "interventions": [
        {
          "name": "TVB-2640 25 mg (US)",
          "type": "DRUG"
        },
        {
          "name": "TVB-2640 50 mg (US)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (US)",
          "type": "DRUG"
        },
        {
          "name": "TVB-2640 50 mg (China)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (China)",
          "type": "DRUG"
        },
        {
          "name": "TVB-2640 75 mg (US)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sagimet Biosciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 142,
      "start_date": "2019-03-22",
      "completion_date": "2021-10-02",
      "has_results": true,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-10-15T11:13:45.004Z",
      "location_count": 12,
      "location_summary": "Chula Vista, California • Montclair, California • Sacramento, California + 9 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03938246"
    },
    {
      "nct_id": "NCT01950520",
      "title": "Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Propranolol",
          "type": "DRUG"
        },
        {
          "name": "Pindolol",
          "type": "DRUG"
        },
        {
          "name": "Dantrolene",
          "type": "DRUG"
        },
        {
          "name": "Magnesium Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Caffeine",
          "type": "DRUG"
        },
        {
          "name": "Qsymia",
          "type": "DRUG"
        },
        {
          "name": "Topiramate",
          "type": "DRUG"
        },
        {
          "name": "Phentermine",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron 50mg",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron 200mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo Cohort 1",
          "type": "DRUG"
        },
        {
          "name": "Placebo Cohort 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Mirabegron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "MALE",
        "summary": "18 Years to 35 Years · Male only"
      },
      "enrollment_count": 47,
      "start_date": "2014-02-07",
      "completion_date": "2024-06-11",
      "has_results": true,
      "last_update_posted_date": "2024-10-16",
      "last_synced_at": "2026-10-15T11:13:45.004Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01950520"
    },
    {
      "nct_id": "NCT05772520",
      "title": "The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "TLL018 tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hangzhou Highlightll Pharmaceutical Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 82,
      "start_date": "2023-01-19",
      "completion_date": "2024-12-23",
      "has_results": true,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-10-15T11:13:45.004Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05772520"
    },
    {
      "nct_id": "NCT03815825",
      "title": "GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Degeneration",
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "IONIS-FB-LRx",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 332,
      "start_date": "2019-03-04",
      "completion_date": "2024-06-12",
      "has_results": false,
      "last_update_posted_date": "2025-03-07",
      "last_synced_at": "2026-10-15T11:13:45.004Z",
      "location_count": 55,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Beverly Hills, California + 47 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03815825"
    },
    {
      "nct_id": "NCT05002998",
      "title": "TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "Teprotumumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 313,
      "start_date": "2021-09-16",
      "completion_date": "2025-12-19",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-15T11:13:45.004Z",
      "location_count": 7,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Palo Alto, California + 4 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05002998"
    },
    {
      "nct_id": "NCT01117038",
      "title": "Drug Interaction Study of Avanafil and Enalapril or Amlodipine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Erectile Dysfunction"
      ],
      "interventions": [
        {
          "name": "avanafil and enalapril",
          "type": "DRUG"
        },
        {
          "name": "avanafil and amlodipine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VIVUS LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "40 Years to 65 Years · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2010-04",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2011-08-10",
      "last_synced_at": "2026-10-15T11:13:45.004Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01117038"
    },
    {
      "nct_id": "NCT02599714",
      "title": "Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced and Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "AZD2014",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 54,
      "start_date": "2015-12-07",
      "completion_date": "2023-11-23",
      "has_results": false,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-10-15T11:13:45.004Z",
      "location_count": 5,
      "location_summary": "Encinitas, California • Sarasota, Florida • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02599714"
    },
    {
      "nct_id": "NCT05309915",
      "title": "A Study of STP707 Administered by IV in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "STP707",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sirnaomics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2022-02-28",
      "completion_date": "2022-08-30",
      "has_results": false,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-10-15T11:13:45.004Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05309915"
    },
    {
      "nct_id": "NCT02435433",
      "title": "A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 399,
      "start_date": "2015-07-20",
      "completion_date": "2021-11-19",
      "has_results": true,
      "last_update_posted_date": "2023-01-20",
      "last_synced_at": "2026-10-15T11:13:45.004Z",
      "location_count": 8,
      "location_summary": "Daly City, California • Los Angeles, California • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02435433"
    },
    {
      "nct_id": "NCT02214433",
      "title": "A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "Placebo IV Solution",
          "type": "DRUG"
        },
        {
          "name": "Debio 1450 IV Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablet or Capsule",
          "type": "DRUG"
        },
        {
          "name": "Debio 1450 Tablet",
          "type": "DRUG"
        },
        {
          "name": "Debio 1450 Capsule",
          "type": "DRUG"
        },
        {
          "name": "Debio 1450 Oral Solution",
          "type": "DRUG"
        },
        {
          "name": "Pantoprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Debiopharm International SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 70,
      "start_date": "2014-08",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2015-02-25",
      "last_synced_at": "2026-10-15T11:13:45.004Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02214433"
    }
  ]
}